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The envelope glycoprotein complex (gp120-gp41) of human immunodeficiency virus type 1 (HIV-1) promotes
the fusion of viral and cellular membranes through formation of the fusion-active six-helix bundle in the gp41
ectodomain. This gp41 core structure consists of three C-terminal helices packed in an antiparallel manner
into hydrophobic grooves on the surface of the N-terminal trimeric coiled coil. Alanine mutations that
destabilize the N- and C-terminal interhelical packing interactions also reduce viral infectivity. Here we show
that viruses bearing these mutations exhibit a marked potentiation of inhibition by peptides that make up the
gp41 core. By contrast, these viruses are unchanged in their sensitivities to soluble CD4, the CXCR4 coreceptor
ligand SDF-1, and human anti-HIV immunoglobulin, reagents that impact the initial, receptor-induced
conformational changes in the envelope glycoprotein. Our results support the notion that these alanine
mutations specifically affect the conformational transition to the fusion-active gp41 structure. The mutations
also increase viral sensitivity to the gp41-directed monoclonal antibody 2F5, suggesting that this broadly
neutralizing antibody may also interfere with this transition. The conformational activation of the HIV-1
envelope glycoprotein likely represents a viable target for vaccine and antiviral drug development.
The envelope glycoprotein of human immunodeficiency vi-
rus type 1 (HIV-1) mediates viral entry by promoting the
fusion of viral and cellular membranes. On the virion surface,
the envelope glycoprotein complex exists as an oligomeric
spike comprising the receptor-binding subunit gp120, which is
anchored to the viral membrane through a noncovalent asso-
ciation with the transmembrane subunit gp41 (for a review, see
reference 32). Considerable evidence indicates that HIV-1
membrane fusion requires a series of conformational changes
in gp41. Numerous studies lead to the following working model
for envelope glycoprotein-mediated membrane fusion (for a
review, see reference 13 and references therein) (Fig. 1A). The
native form of gp41 on the surface of the virus is stabilized by
interactions with gp120, which are altered upon the binding of
gp120 to CD4 and a coreceptor. The prehairpin intermediate
of gp41 is subsequently formed by folding of the N-terminal
trimeric coiled coil, leading to the insertion of the N-terminal
hydrophobic fusion-peptide region into the target membrane.
This prehairpin intermediate then collapses to form the six-
helix bundle structure in which the C-terminal regions pack
into the hydrophobic grooves of the N-terminal coiled-coil
trimer in an antiparallel manner. The formation of this trimer-
of-hairpins structure brings the viral and cellular membranes
into close apposition. The free energy made available by the
formation of this highly stable gp41 core is thought to contrib-
ute to overcoming the energy barrier to membrane fusion (e.g.,
20).
The crucial role of interhelical packing interactions between
the N- and C-terminal regions of the gp41 ectodomain pro-
vides an opportunity for antiviral intervention (13, 41). For
example, peptides corresponding to the C-terminal heptad-
repeat region of gp41, termed C peptides, are capable of in-
hibiting entry of HIV-1 at nanomolar concentrations (24, 28,
49). One such peptide, T20, has been shown to have antiviral
activity in humans (25). Biochemical and structural studies
strongly suggest that C peptides act in a dominant-negative
manner by binding to the N-terminal coiled-coil region of gp41
in its prehairpin intermediate state, thereby interfering with its
transition to the fusion-active six-helix bundle structure (6, 8,
17, 28, 45, 49). Similarly, peptides derived from the N-terminal
heptad-repeat region of gp41 (called N peptides) are thought
to block HIV-1 fusion by binding to the C-helix region of the
gp41 intermediate (Fig. 1A) (7, 28, 48). N peptides may also
act by intercalating into the N-helix coiled-coil structure (3).
Because N peptides aggregate in solution, they are less potent
inhibitors than the C peptides (28). However, soluble forms of
the trimeric N peptide inhibit with nanomolar potency similar
to that of the C peptides (12, 38).
Mutations in gp41 that alter the interhelical packing inter-
actions can destabilize the fusion-active gp41 core structure
and reduce the ability of the envelope glycoprotein to mediate
membrane fusion (4, 21, 22, 31, 40, 44, 46, 47). By using
alanine-scanning mutagenesis, we have recently identified sev-
eral amino acid residues in the interhelical e and g positions of
the N-peptide region that are critical for membrane fusion
activity (31). Alanine substitutions at these positions decrease
the thermal stability of the six-helix bundle and markedly re-
duce the ability of the mutant envelope glycoproteins to me-
diate cell-cell fusion (31). These results suggest that the desta-
bilizing alanine mutations render the formation of the trimer-
of-hairpins structure less favorable and perhaps increase exposure
of the transient prehairpin intermediate (31).
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According to this idea, we surmised that these alanine mu-
tations might render the virus more sensitive to inhibition by N
and C peptides that target the prehairpin intermediate. In
order to directly test this hypothesis, we constructed recombi-
nant viruses bearing single alanine mutations at the interhelical
Leu-556, Leu-565, and Val-570 positions. We also generated
recombinant viruses bearing mutations at Gln-551 and Gln-
563, mutations that have little or no effect on the stability of the
gp41 core or on the fusion activity of the envelope glycoprotein
(Fig. 1B and Table 1).
Characterization of mutant viruses. Infectious HIV-1
NL4-3 (2) proviruses bearing the alanine mutations in gp41
were constructed for this study. These mutant envelope glyco-
proteins included fusion-deficient phenotypes (viz., L556A,
L565A, and V570A) as well as fusion-intact controls (viz.,
Q551A and Q563A) (31). The alanine mutations were trans-
ferred from the HXB2 envelope glycoprotein expression plas-
mid (31) to the NL4-3 provirus by using a 1.6-kb NheI-XhoI
restriction endonuclease fragment which encodes the envelope
glycoprotein from the C3 region of gp120 through the entire
gp41 protein. The wild-type HXB2 fragment was also trans-
FIG. 1. A working model for gp41-mediated membrane fusion and its inhibition by peptides. (A) The native envelope glycoprotein complex on
the virion surface undergoes conformational changes upon binding to CD4 and the coreceptor, and the gp41 subunit is released to form a
prehairpin intermediate in which the hydrophobic N-terminal fusion peptide of gp41 is inserted into the cellular membrane and the N-terminal
heptad-repeat regions (N helix) form a trimeric coiled coil. Productive infection is mediated by the collapse of the prehairpin intermediate to form
the fusion-active gp41 core in which the C-terminal heptad-repeat regions (C helix) pack into the hydrophobic grooves of the N-terminal coiled
coil. The formation of the trimer-of-hairpins brings the viral and cellular membranes into apposition to promote fusion. Inhibition of infection by
N and C peptides is mediated by peptide binding to the cognate gp41 helix. The N peptide is shown binding to the C helix as a trimeric coiled coil.
Peptide binding inactivates the envelope glycoprotein complex and blocks viral infectivity. (B) The amino acid sequences of the N36 and C34
peptides are shown above the N- and C-terminal heptad-repeat regions in this linear representation of gp41. The positions of the interhelical
alanine mutations that result in fusion-intact (open circles) and fusion-deficient (closed circles) envelope glycoproteins are indicated. The residues
are numbered according to their positions in HXB2 gp160.
TABLE 1. Summary of mutant envelope glycoproteins and viruses
Envelope
glycoprotein
Cell-cell
fusion
activitya
Tm of
gp41 six-helix
bundle (°C)a,b
Viral
infectivityc
gp120
per viriond
(arbitrary units)
Wild type  70 4,500 0.15
L556A  64 330 0.13
L565A  50 120 0.20
V570A  56 15 0.16
Q551A  74 2,500 0.16
Q563A  68 21,000 0.27
a The results are from reference 31.
b The melting temperature (Tm) of the gp41 six-helix bundle was determined
in the N34(L6)C28 model (29).
c p24 was determined by antigen capture enzyme-linked immunosorbent assay
(Beckman Coulter, Inc.). Nominal viral infectivity (number of foci per nanogram
of p24) was calculated by using a dilution of virus that produced 100 foci in a
96-well U87-CD4-CXCR4 cell microculture assay.
d The relative amount of gp120 per virion was estimated by Western blot
analysis of centrifugally purified virions (51). gp120 was determined with the
deglycosylated 55-kDa polypeptide of gp120 (31) and the anti-gp120 MAb
Chessie 12 (1). Virion core protein p17 was assessed using immunoglobulin from
HIV-infected persons (HIVIG). Antibody binding was visualized by ECL-Plus
(Amersham Pharmacia Biotech), and fluorescence was quantitated using a Fuji
FLA-3000G analyzer. The ratio of fluorescence intensities is shown.
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ferred to generate the wild-type provirus bearing a chimeric
NL4-3/HXB2 env gene. The molecularly cloned NL4-3 and
HXB2 env genes were derived from the same human T-cell
leukemia virus strain III/lymphadenopathy-associated virus/
HIV-1 strain IIIb population and are 97% identical (2, 36).
In the case of Q551A, the provirus was constructed with the
use of a BamHI site within the sequence encoding the cyto-
plasmic domain of gp41 rather than the XhoI site.
The wild-type and mutant provirus plasmids were used to
generate infectious virus stocks by FuGene-6-mediated trans-
fection of COS-7 cells (51). Western blot analysis of centrifu-
gally purified virions demonstrated comparable levels of enve-
lope glycoprotein in the wild-type and mutant virion particles
(data not shown). These results confirmed that the synthesis,
transport, proteolytic cleavage, and virion incorporation of
these fusion-deficient and fusion-intact glycoproteins were un-
affected by the alanine mutations (Table 1).
Infectivity of the mutant virions was determined by serial
dilution in a U87-CD4-CXCR4 cell infectivity assay (19, 26)
(Table 1). Among the viruses bearing a fusion-deficient enve-
lope glycoprotein, L556A was 14-fold-less infectious than the
wild-type virus, whereas L565A and V570A were approxi-
mately 40-fold- and 300-fold-less infectious, respectively. This
ordering of viral infectivity is identical to that observed for the
envelope glycoproteins in cell-cell fusion assays (31) and gen-
erally corresponds to the measured reduction in the thermal
stability of the gp41 core. The least destabilizing mutation
(L556A) resulted in the most infectious virus whereas the more
highly destabilized mutants (L565A and V570A) were severely
debilitated in infectivity. The infectivity of virions containing
the stable and fusion-intact envelope glycoproteins (Q551A
and Q563A) was similar to that of the wild-type virus.
Destabilizing mutations do not affect early steps in binding
and entry. The working model for envelope glycoprotein-me-
diated fusion (Fig. 1A) defines two sequential steps comprising
(i) the initial interactions between the gp120 moiety of the
envelope glycoprotein complex and its cellular receptor and
coreceptor, and (ii) the triggering of the membrane-fusion
activity of gp41. Based on this model, we anticipated that
mutations that destabilize the interhelical packing interactions
within the gp41 fusion-active core should not perturb the early
processes of CD4 and coreceptor binding.
To directly test this hypothesis, we examined the sensitivity
of the viruses to two inhibitors that target early, gp120-medi-
ated steps in binding and entry: soluble CD4 (sCD4) (10) and
the CXCR4 chemokine SDF-1 (34). We reasoned that po-
tential alterations in the process of CD4 and coreceptor bind-
ing might be manifested in differential sensitivities to these
specific inhibitors. In these studies, wild-type and mutant vi-
ruses were exposed to serial dilutions of sCD4 or SDF-1 for
1 h at 37°C, and the mixture was used to infect U87-CD4-
CXCR4 cells. The virus input into the assay was predeter-
mined to yield approximately 100 to 200 infected-cell foci in
the 96-well microculture assay. Two days after infection, cells
were immunochemically stained and infected cells were enu-
merated microscopically (26). As demonstrated by the results
shown in Fig. 2A and 2B, inhibition of infection by sCD4 or by
blockade of the CXCR4 coreceptor was entirely unaffected in
the fusion-deficient (L556A, L565A, and V570A) and fusion-
intact (Q551A and Q563A) viruses.
We extended these findings to examine the sensitivity of the
fusion-deficient and fusion-intact viruses to neutralization by
HIVIG, an immunoglobulin preparation from HIV-infected
persons (35). The bulk of HIVIG’s neutralization activity
against laboratory-adapted strains such as those studied here is
directed to the third variable (V3) loop of gp120 (43). Anti-
body binding to the V3 loop may affect neutralization by per-
turbing CD4-induced changes that contribute to the formation
of the coreceptor binding site in gp120 (37). As shown in Fig.
2C, sensitivity to neutralization by HIVIG was largely compa-
rable in the fusion-deficient and fusion-intact viruses. Thus,
neutralization by HIVIG does not appear to interact with the
gp41-destabilizing mutations and in this regard is analogous to
the inhibition seen by the other gp120-directed reagents, sCD4
and SDF-1.
From these results, we conclude that the destabilizing mu-
tations within the N-terminal helix do not significantly affect
the structures and conformational changes that mediate CD4
and coreceptor binding. Nor do the destabilizing mutations
impart global or pleiotropic effects upon the envelope glyco-
protein complex that render the debilitated viruses fragile in a
nonspecific manner.
Destabilizing mutations affect conformational changes in
gp41. We reasoned that mutations that destabilize the inter-
helical packing interactions within the fusion-active gp41 tri-
mer-of-hairpins might correspondingly favor the preceding
prehairpin intermediate. Therefore, we examined the sensitiv-
ities of the mutant viruses to peptides that specifically target
the N- and C-terminal helices within the prehairpin interme-
diate. N36 and C34 peptides (Fig. 1B) were produced as de-
scribed previously (30). We initially focused on the N36 pep-
tide because this peptide binds to wild-type C-terminal helix
sequences that are identical in all the mutant viruses.
Wild-type and mutant viruses were incubated with serial
dilutions of the N36 peptide, and inhibition was assessed in
U87-CD4-CXCR4 cell microcultures. N36 was soluble to 4
M, and higher concentrations were precluded by peptide
insolubility in the cell culture medium. Among wild-type and
fusion-intact (Q551A and Q563A) viruses (Fig. 3A), little or no
inhibition was observed in the presence of a 4-M concentra-
tion of N36, consistent with previous findings that N peptides
exhibit relatively low potency (27, 28, 48).
By contrast, all three fusion-deficient alanine mutations that
destabilize the interhelical packing interaction in the six-helix
bundle structure dramatically increased the sensitivity of the
corresponding mutant viruses to inhibition by N36 (Fig. 3A).
Ninety percent inhibition (IC90) of the fusion-deficient viruses
L556A, L565A, and V570A was seen at 4, 2.8, and 1.2 M
concentrations of N36, respectively. The rank ordering of the
susceptibilities to inhibition by N36 corresponds to the relative
reduction in viral infectivity. Because peptide binding is
thought to be with wild-type C-terminal helix sequence in all
cases, these findings suggest that the N-helix mutations that
destabilize the trimer-of-hairpin structure increase exposure of
the vulnerable prehairpin target.
These data suggest that the destabilizing alanine mutations
in the L556A, L565A, and V570A viruses exert a specific and
circumscribed effect on the latter steps of gp41-mediated mem-
brane fusion and in particular on the formation of the fusion-
active gp41 core. These mutations that destabilize the inter-
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helical packing interactions within the six-helix bundle in vitro
appear not to favor the conformational transition from the
prehairpin intermediate in vivo. Interference in this transition
within the dynamic envelope glycoprotein strongly diminishes
viral infectivity and specifically increases viral sensitivity to N
peptides that target this critical process.
In contrast to that of the N36 peptide, the stability of binding
of the C34 peptide to the different alanine-substituted N-ter-
minal helices is expected to vary in accordance with the ther-
mal stabilities determined in the N34(L6)C28 model (Table 1).
Thus, the analysis of inhibition by C34 offers the opportunity to
probe the balance between two complex and counteracting
influences: (i) the reduced stability of peptide binding to the
mutated N-terminal helix and (ii) the increased exposure of the
helical regions in the prehairpin intermediate target. In these
studies, the fusion-deficient viruses L556A, L565A, and V570A
again showed a marked increase in sensitivity to inhibition by
C34 (IC90 values of 5, 0.5, and 0.0004 nM, respectively [Fig.
3B]). The wild-type and fusion-intact mutant (Q551A and
Q563A) viruses with an IC90 of approximately 100 nM were
inhibited. Thus, the predominant effect is one of increased
FIG. 2. Sensitivity to soluble CD4, SDF-1 and HIVIG. The U87-
CD4-CXCR4 cell microculture virus inhibition assay is described in
the text (26). Inhibition is indicated as the percent reduction in the
number of infected-cell foci relative to the control virus input. (A) The
sCD4 ectodomain was obtained from Progenics Pharmaceuticals, and
(B) the CXCR4 chemokine SDF-1 was kindly provided by Ian Clark-
Lewis (University of British Columbia). (C) HIVIG, an immunoglob-
ulin preparation from HIV-infected persons, was provided by Fred
Prince (New York City Blood Center). In each case, the results of a
representative study performed in duplicate are shown; replicate ex-
periments yielded concordant results. Wild type (circle) and fusion-
intact mutants Q551A (square) and Q563A (diamond) are shown as
open symbols. Fusion-deficient mutants L556A (square), L565A (cir-
cle), and V570A (diamond) are shown as closed symbols.
FIG. 3. Inhibition by N36 and C34 peptides. The U87-CD4-
CXCR4 cell inhibition assay and the mutant viruses are described in
the legend to Fig. 2. Inhibition by the N36 peptide (A) and the C34
peptide (B) is shown. The measurement of C36 inhibition was ex-
tended to 1 fM of peptide (data not presented).
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sensitivity to peptide inhibition. It appears that in a dynamic
system, the increased exposure of the prehairpin target con-
tributes to more inhibition than does the counteracting influ-
ence of decreased peptide binding stability. The mechanistic
basis for this outcome is unclear but likely reflects the com-
plexity of the competing processes within the intact envelope
glycoprotein.
This complexity is also reflected in the broad range of inhi-
bition of L565A and V570A, the most destabilized and debil-
itated viruses. For instance, L565A virus infectivity was inhib-
ited by 50% at 0.008 pM C34, a concentration approximately
105-fold below the IC90. This finding suggests a second route of
inhibition in these mutants, although the mechanism is un-
known.
Neutralization by MAb 2F5. Our data support the simple
model that alanine mutations that destabilize interhelical pack-
ing interactions act specifically by rendering the conforma-
tional transition to the fusion-active trimer-of-hairpins struc-
ture less favorable. We therefore wanted to utilize these
specific effects to study the mechanism of virus inhibition by
the unique and broadly neutralizing gp41-directed human
monoclonal antibody (MAb) 2F5 (9, 11, 42). This MAb targets
a predominantly linear epitope (ELDKWA) that lies distal to
the C-terminal heptad-repeat sequence (33) in the membrane-
proximal region of gp41, a region that has been independently
identified as an important determinant of membrane fusion
(39, 50).
To assess whether neutralization by MAb 2F5 was affected
by the destabilizing mutations, we determined the neutraliza-
tion sensitivity of the fusion-intact and fusion-deficient viruses.
Ninety-percent inhibition of the wild-type virus and the Q551A
fusion-intact mutant required more than 50 g of MAb 2F5/ml
(Fig. 4). By contrast, the fusion-deficient viruses L556A and
L565A were inhibited by 90% at 10 g/ml, and the highly
debilitated V570A virus displayed an IC90 of 3 g/ml. Thus,
neutralization by MAb 2F5 was strikingly and specifically po-
tentiated by the destabilizing mutations.
Interestingly, the Q563A fusion-intact virus displays a sen-
sitivity phenotype similar to that of the less destabilized mu-
tants L556A and L565A (IC90 of Q563A, 20 g/ml). This
mutant virus was also somewhat sensitive to neutralization by
HIVIG (Fig. 2C) and may suffer a more generalized vulnera-
bility to antibody-mediated neutralization.
Taken together, our results suggest that MAb 2F5 may act
by inhibiting the conformational transition to the fusion-active
structure. Indeed, Gorny and Zolla-Pazner (18) have previ-
ously shown that MAb 2F5 binding to a synthetic C43 peptide
is occluded by prior formation of the C43-N51 peptide com-
plex. Our findings with mutant viruses provide biological evi-
dence that the neutralization activity of MAb 2F5 targets the
transition to the fusion-active gp41 structure.
Among other gp41-directed MAbs tested (MAbs F240 [5],
NC-1 [23], 50-69D, 1281, 98-6D, and 246-D [18]), none neu-
tralized the parental virus and none was able to evoke neutral-
ization of the fusion-deficient mutants (data not shown). These
examples may reflect insufficient potency or simply the lack of
antibody binding.
Discussion. Our study provides a novel demonstration in
support of the current model for gp41-mediated membrane
fusion and its inhibition by N and C peptides. Based on exten-
sive genetic and biophysical evidence (for a review, see refer-
ence 13 and references therein), the model proposes a meta-
stable prehairpin gp41 intermediate that folds upon itself to
form the stable trimer-of-hairpins structure in which C-termi-
nal helices pack into hydrophobic grooves on a central coiled-
coil trimer of N-terminal helices. The energy made available by
formation of the stable gp41 core is thought to contribute to
membrane fusion. Destabilization of the N- and C-interhelical
packing interactions by mutation renders the transition to the
fusion-active trimer-of-hairpins less favorable and reduces the
ability of the mutant virus to complete membrane fusion and
initiate infection.
Our study provides direct evidence for the existence of a
discrete and relatively long-lived prehairpin intermediate that
is targeted by N and C peptides (6, 17, 40, 45). We suggest that
mutations that destabilize the interhelical packing interactions
in the trimer-of-hairpins structure correspondingly increase
the lifetime of the prehairpin intermediate. In this model, the
relative antiviral activity of gp41 peptides is determined by a
competition between formation of the trimer-of-hairpins struc-
ture and the binding of peptide to the prehairpin intermediate.
As the rate of trimer-of-hairpins formation is decreased by
mutation, there is more opportunity for peptide binding and
thus more of the prehairpin intermediate is diverted into an
inactivated form.
Inhibitors that target the conformational transition of gp41
to the fusion-active state represent a new and promising class
of antiviral drugs (14, 16). Such antiviral agents might be ex-
pected to interact synergistically to enhance the antiviral po-
tency of C peptides that are currently in clinical study, by
increasing exposure of the vulnerable prehairpin intermediate.
We have analyzed the interactions between the effects of
specific envelope glycoprotein mutations and those of defined
antiviral agents in order to obtain additional insight into the
respective molecular targets (15). In particular, our finding
that neutralization by MAb 2F5 is potentiated by the destabi-
lizing mutations suggests that this broadly neutralizing MAb
may itself bind to a prefusogenic structure and may act by
FIG. 4. Neutralization by MAb 2F5. The assay and the mutant
viruses are as described in the legend to Fig. 2. MAb 2F5, a gp41-
directed and broadly neutralizing MAb, from Hermann Katinger (In-
stitute for Applied Microbiology) was provided by Anthony Conley
(Merck Research Laboratories).
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interfering with the formation of the fusogenic trimer-of-hair-
pins. Recently, other neutralizing human MAbs directed to the
same membrane-proximal region of gp41 have been identified
(52) and these may act similarly to MAb 2F5.
Further characterization of the conformational changes in
the HIV-1 envelope glycoprotein will facilitate efforts to de-
velop novel therapeutics and vaccine immunogens. In particu-
lar, mutations in the envelope glycoprotein that specifically
destabilize the trimer-of-hairpins structure may enhance the
presentation of intermediate conformations for vaccine devel-
opment. Continued analysis of this critical and vulnerable tran-
sition in gp41 may point to unique targets for antiviral inter-
vention.
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